Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Intertumoral Heterogeneity within Medulloblastoma Subgroups.

    Cancer Cell 2017 Jun;31(6):737-754.e6
    The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada; Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. Electronic address:
    While molecular subgrouping has revolutionized medulloblastoma classification, the extent of heterogeneity within subgroups is unknown. Similarity network fusion (SNF) applied to genome-wide DNA methylation and gene expression data across 763 primary samples identifies very homogeneous clusters of patients, supporting the presence of medulloblastoma subtypes. After integration of somatic copy-number alterations, and clinical features specific to each cluster, we identify 12 different subtypes of medulloblastoma. Integrative analysis using SNF further delineates group 3 from group 4 medulloblastoma, which is not as readily apparent through analyses of individual data types. Two clear subtypes of infants with Sonic Hedgehog medulloblastoma with disparate outcomes and biology are identified. Medulloblastoma subtypes identified through integrative clustering have important implications for stratification of future clinical trials.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1016/j.ccell.2017.05.005DOI ListingPossible

    Similar Publications

    Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
    Curr Pediatr Rev 2015 ;11(2):106-19
    Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India.
    Medulloblastoma, the most common primary pediatric malignant brain tumor is a molecularly heterogeneous disease with different developmental origins, distinct phenotypes, diverse biological behaviour, and contrasting clinical outcomes. The current clinico-radiological risk-classification fails to take account of this heterogeneity and existent prognostic variability. It is widely accepted that dysregulation of normal developmental processes constitute a key mechanism of tumorigenesis in at least a subset of medulloblastomas. Read More
    Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Lancet Oncol 2017 Jul 22;18(7):958-971. Epub 2017 May 22.
    Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. Electronic address:
    Background: International consensus recognises four medulloblastoma molecular subgroups: WNT (MB), SHH (MB), group 3 (MB), and group 4 (MB), each defined by their characteristic genome-wide transcriptomic and DNA methylomic profiles. These subgroups have distinct clinicopathological and molecular features, and underpin current disease subclassification and initial subgroup-directed therapies that are underway in clinical trials. However, substantial biological heterogeneity and differences in survival are apparent within each subgroup, which remain to be resolved. Read More
    The whole-genome landscape of medulloblastoma subtypes.
    Nature 2017 07;547(7663):311-317
    Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Read More
    Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
    Neurotherapeutics 2017 04;14(2):265-273
    Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA.
    Recent advances in cancer genomics have revealed 4 distinct subgroups of medulloblastomas, each with unique transcription profiles, DNA alterations and clinical outcome. Molecular classification of medulloblastomas improves predictions of clinical outcome, allowing more accurate matching of intensity of conventional treatments with chemotherapy and radiation to overall prognosis and setting the stage for the introduction of targeted therapies. Read More